A PSMA scan is a nuclear medicine imaging technique used in the diagnosis and staging of prostate cancer. It is carried out by injection of a radiopharmaceutical with a positron or gamma emitting radionuclide and a prostate-specific membrane antigen (PSMA) targeting ligand. After injection, imaging of positron emitters such as gallium-68 (68Ga), copper-64 (64Cu), and fluorine-18 (18F) is carried out with a positron emission tomography (PET) scanner. For gamma emitters such as technetium-99m (99mTc) and indium-111 (111In) single-photon emission computed tomography (SPECT) imaging is performed with a gamma camera.
As well as the diagnosis and staging of prostate cancer, PSMA imaging can also be used to assess suitability for and plan treatment with external beam radiotherapy and PSMA-targeted radionuclide therapy.[1][2]
^Wang, Fujin; Li, Zhifeng; Feng, Xiaoqian; Yang, Dazhuang; Lin, Mei (March 2022). "Advances in PSMA-targeted therapy for prostate cancer". Prostate Cancer and Prostatic Diseases. 25 (1): 11–26. doi:10.1038/s41391-021-00394-5. PMID 34050265. S2CID 235241529.
^Mena, Esther; Lindenberg, Liza; Choyke, Peter (March 2022). "The Impact of PSMA PET/CT Imaging in Prostate Cancer Radiation Treatment". Seminars in Nuclear Medicine. 52 (2): 255–262. doi:10.1053/j.semnuclmed.2021.12.008. PMC 8960055. PMID 35016755.
A PSMAscan is a nuclear medicine imaging technique used in the diagnosis and staging of prostate cancer. It is carried out by injection of a radiopharmaceutical...
the United States. The FDA considers 68Ga PSMA-11 to be a first-in-class medication. Gallium PSMAscanning is recommended primarily in cases of biochemical...
(worst prognosis). The extent of cancer spread is assessed by MRI or PSMAscan – a positron emission tomography (PET) imaging technique where a radioactive...
randomised phase 3 trial ("ProPSMA study") was published comparing Gallium-68 PSMA PET/CT to standard imaging (CT and bone scan). This 300 patient study conducted...
the PSMA radioligand therapy (Pluvicto) requires the patient to have end-stage prostate cancer that has metastasized in other organs, the PSMA ligand...
pulmonary indications. 177Lu-PSMA-617 and 68Ga-PSMA-617 are in development to treat, image, monitor and stage prostate cancer. PSMA-617 is a ligand of prostate-specific...
nasopharynx overlying the torus tubarius. The tubarial salivary glands bind to PSMA, which is how they were discovered. The glands were discovered by a group...
177Lu-PSMA or 225Ac-PSMA therapies. For local recurrence, 68Ga-PSMA PET/MR or PET/CT in combination with mpMR is most appropriate. PSMA PET/CT may be potentially...
diagnostics. Mirzaei and his team are the first center which is applying Cu-64 PSMA in prostate cancer. Somatostatin receptor scintigraphy (SRS) and therapy...
period to prepare the radiopharmaceutical and trace it, such as a fibrinogen scan to diagnose clotting. I-125's gamma radiation is of medium penetration, making...
Excellence. 29 August 2018. Retrieved 3 September 2018. Kabasaka, Levent. "Lu-177-PSMA Real World Clinical Study: Out-patient or In-patient Treatment" (PDF). BNMS...
Yongxiang; Yin, Hongling; Hu, Shuo (2021). "18F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report"....
Nitin; El-Haddad, Ghassan; Park, Chandler H. (June 23, 2021). "Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer". New England Journal...
Leonardo Lima; Lemos, Gustavo Caserta (2020-02-24). "Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate...
treatment. Results from Phase 2 trial recommended G-202 as a first-in-class PSMA-targeted prodrug and that it move to clinical trials. Current research includes...
Positron-emitting and Fluorescent (HD-GPF) reporter system uses a human protein, PSMA and non-immunogenic, and a small molecule that is positron-emitting (boron...
location intelligence tool, called GeoVision, which uses data provided by PSMA Australia and allows companies to "visualise, analyse, and ultimately make...
resources. Since 2017, he steered the development of [68Ga]Ga-/[177Lu]Lu-PSMA-based theranostics and peptide receptor radioligand therapy (PRLT) in metastatic...
Global Information